Shareholder Alert: Robbins LLP Announces It Is Investigating Gossamer Bio, Inc. (GOSS) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs shareholders it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) for potential violations of federal securities laws and breaches of fiduciary duty by its board members and executive officers. In its initial public offering, Gossamer offered approximately 19.8 million shares at $19.00 per share, raising gross proceeds of $317.4 million. Gossamer's leading product is its GB001 drug, which is a DP2 antagonist drug for the treatment of asthma. However, on December 16, 2019, Novartis announced it was terminating the development of its similar DP2 antagonist drug for asthma after it failed a pair of phase 3 clinical trials. On this news, Gossamer's stock plummeted 37% to close at $15.96 per share, representing a 16% decline from its IPO price.

If you suffered a loss as a result of Gossamer's misconduct, click here.

Gossamer Bio, Inc. (GOSS) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
[phone]
[e-mail]
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.